Akari Therapeutics Plc
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity (Deficit)
Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit)
(amounts in thousands, except share data)
| Share Capital · Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Ordinary Shares, · Additional · Capital · Other · Total | |||||||
| $0.0001 par value · Paid-in- · Redemption · Comprehensive · Accumulated · Shareholders’ | |||||||
| Shares | Amount | Capital | Reserve | Loss | Deficit | Equity | |
| Balance, December 31, 2024 | 53,186,919,523 | $5,319 | $212,706 | $52,194 | $(738) | $(247,252) | $22,229 |
| Issuance of share capital related to financing, net of issuance costs | 4,566,062,000 | 457 | 1,785 | — | — | — | 2,242 |
| Stock-based compensation | — | — | 1,015 | — | — | — | 1,015 |
| Foreign currency translation | — | — | — | — | (35) | — | (35) |
| Net loss | — | — | — | — | — | (3,705) | (3,705) |
| Balance, March 31, 2025 | 57,752,981,523 | $5,776 | $215,506 | $52,194 | $(773) | $(250,957) | $21,746 |
| Issuance of share capital related to financing, net of issuance costs | 5,753,878,000 | 575 | 3,829 | — | — | — | 4,404 |
| Issuance of share capital on conversion of convertible notes, related party | 387,880,000 | 39 | 270 | — | — | — | 309 |
| Issuance of share capital for services | 1,002,900,000 | 100 | 522 | — | — | — | 622 |
| Vesting of restricted shares | 331,822,000 | 33 | — | — | — | — | 33 |
| Stock-based compensation | — | — | 719 | — | — | — | 719 |
| Foreign currency translation | — | — | — | — | (333) | — | (333) |
| Net loss | — | — | — | — | — | (1,895) | (1,895) |
| Balance, June 30, 2025 | 65,229,461,523 | $6,523 | $220,846 | $52,194 | $(1,106) | $(252,852) | $25,605 |
| Modification of warrants in connection with issuance of notes payable | — | — | 2,643 | — | — | — | 2,643 |
| Reclassification and modification of warrants in connection with amendment of convertible notes | — | — | 192 | — | — | — | 192 |
| Stock-based compensation | — | — | 685 | — | — | — | 685 |
| Foreign currency translation | — | — | — | — | (38) | — | (38) |
| Net loss | — | — | — | — | — | (6,400) | (6,400) |
| Balance, September 30, 2025 | 65,229,461,523 | $6,523 | $224,366 | $52,194 | $(1,144) | $(259,252) | $22,687 |
| Share Capital · Accumulated · Total | |||||||
|---|---|---|---|---|---|---|---|
| Ordinary Share, · Additional · Capital · Other · Shareholders’ | |||||||
| $0.0001 par value · Paid-in- · Redemption · Comprehensive · Accumulated · Equity | |||||||
| Shares | Amount | Capital | Reserve | (Income) Loss | Deficit | (Deficit) | |
| Balance, December 31, 2023 | 13,234,315,298 | $1,324 | $174,754 | $52,194 | $(1,040) | $(227,461) | $(229) |
| Issuance of share capital related to financing, net of issuance costs | 2,641,228,000 | 264 | 1,400 | — | — | — | 1,664 |
| Vesting of restricted shares | 97,578,000 | 10 | (7) | — | — | — | 3 |
| Stock-based compensation | — | — | 296 | — | — | — | 296 |
| Foreign currency translation | — | — | — | — | 279 | — | 279 |
| Net loss | — | — | — | — | — | (5,566) | (5,566) |
| Balance, March 31, 2024 | 15,973,121,298 | $1,598 | $176,443 | $52,194 | $(761) | $(233,027) | $(3,553) |
| Issuance of share capital related to financing, net of issuance costs | 8,059,508,000 | 806 | 6,145 | — | — | — | 6,951 |
| Issuance of share capital for services | 91,396,000 | 9 | (9) | — | — | — | — |
| Vesting of restricted shares | 285,697,400 | 29 | (29) | — | — | — | — |
| Shares withheld for payroll taxes | (120,490,000) | (12) | 12 | — | — | — | — |
| Stock-based compensation | — | — | 445 | — | — | — | 445 |
| Foreign currency translation | — | — | — | — | 12 | — | 12 |
| Net loss | — | — | — | — | — | (7,558) | (7,558) |
| Balance, June 30, 2024 | 24,289,232,698 | $2,430 | $183,007 | $52,194 | $(749) | $(240,585) | $(3,703) |
| Proceeds from issuance of restricted shares | — | — | 26 | — | — | — | 26 |
| Shares withheld for payroll taxes | (1,175) | — | (193) | — | — | — | (193) |
| Stock-based compensation | — | — | 248 | — | — | — | 248 |
| Foreign currency translation | — | — | — | — | (177) | — | (177) |
| Net loss | — | — | — | — | — | (2,895) | (2,895) |
| Balance, September 30, 2024 | 24,289,231,523 | $2,430 | $183,088 | $52,194 | $(926) | $(243,480) | $(6,694) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.